There are 11 new IPOs this week expected to hit the market. According to Renaissance Capital, a manager of IPO-focused ETFs, the 11 deals could raise a combined $1.4 billion.
The 2015 IPO market has been abnormally slow compared to last year. In fact, there are more IPOs this week than in all of August.
There have only been 131 deals so far in 2015, down nearly 40% from the same period in 2014. Out of the 134 IPOs so far this year, 61 of them have been from the healthcare sector.
The most anticipated deal on this week's busy IPO calendar is Performance Food Group Co. (NYSE: PFGC).
Performance Food Group is the third-largest foodservice distributor in the United States after SYSCO Corp. (NYSE: SYY) and U.S. Foods. The company's foodservice segment serves independent restaurants and constitutes 59% of its sales. Its vending segment serves snack foods to offices, colleges, and big box retailers and makes up 16% of its sales.
The 140-year-old company posted $15.3 billion in sales between June 2014 and June 2015. Performance Food Group will raise $341 million by selling 14.5 million shares at a $22 to $25 price range. It's valued at $2.4 billion and will hit the market on Thursday, Oct. 1.
Here are 10 more new IPOs this week on the upcoming IPO calendar...
10 More New IPOs This Week
Surgery Partners Inc. (Nasdaq: SGRY) is a medical company that owns or operates 99 surgical facilities across 28 states. The Tennessee-based firm booked $713 million in sales between June 2014 and June 2015. The Surgery Partners IPO is the largest deal this week. It hopes to raise $350 million by offering 14.3 million shares at a price range of $23 to $26. The firm commands a market valuation of $1.2 billion and will debut on Thursday, Oct. 1.
Money Morning Members: Keep reading for nine more new IPOs this week. For those new to Money Morning, sign up to keep reading - it's completely free...
NovoCure Ltd. (Nasdaq: NVCR) markets a wearable electric device called Optune. It's used for treating a rare form of brain cancer called glioblastoma. Optune uses a Tumor Treating Field, a low-intensity electric field that disrupts cell division through interaction with molecules. The device received FDA approval in 2011 and has treated over 1,600 patients. NovoCure has received more than $450 million in institutional and venture funding. It will generate $344 million by selling 12.5 million shares at a $26 to $29 price range. The company is valued at $2.6 billion and will begin trading on Friday, Oct. 2.
[mmpazkzone name="in-story" network="9794" site="307044" id="137008" type="4"]
Edge Therapeutics Inc. (Nasdaq: EDGE) is a biotech firm developing sustained exposure therapies for bleeding related to brain hemorrhages. The company follows last week's three biotech IPOs, each of which traded up 30% by Friday's close. Edge is set for an $85 million deal by selling 5.67 million shares at a price range of $14 to $16. It commands a market valuation of $435 million and will hit the market on Thursday, Oct. 1.
Strongbridge Biopharma Plc. (Nasdaq: SBBP) will raise $76 million by offering 4.25 million shares for $17.93 each. The late-stage biotech will start trading on Friday, Oct. 2.
Mirna Therapeutics Inc. (Nasdaq: MIRN) will generate $65 million by selling 4.65 million shares at a $13 to $15 price range. The liver cancer biotech will debut on Wednesday, Sept. 30.
Sole Elite Group Ltd. (Nasdaq: SOLE) hopes to raise $33 million by offering 3 million shares at a price range of $10 to $12. After multiple delays, the Chinese shoe sole company plans to hit the market sometime this week.
Fuling Global Inc. (Nasdaq: FORK) is set for a $30 million deal by offering 5 million shares at a $5 to $7 price range. The Chinese producer of plastic cutlery will begin trading on Thursday, Oct. 1.
SynCardia Systems Inc. (Nasdaq: TAHT) will raise $28 million by selling 2.5 million shares at a price range of $10 to $12. The artificial heart manufacturer has not listed a specific date but will hit the market sometime this week.
Cerecor Inc. (Nasdaq: CERC) hopes to generate $27 million by offering 4.23 million shares at a $6 to $7 price range. The depressive disorder biotech will go public sometime this week.
Boxlight Corp. (Nasdaq: BOXL) is set to raise $10 million by selling 1.11 million shares at an $8 to $10 price range. The classroom materials producer has been delayed multiple times but hopes to start trading sometime this week.
Follow us on Twitter at @AlexMcGuire92 and @moneymorning.
How to Safely Profit from Any IPO: Investing in newly issued stocks can seem like an exciting way to earn huge profits. But with institutional investors and other Wall Street "VIPs" cheating the market for quick gains, the IPO process is a rigged game nowadays. That's why we've outlined the three best IPO investing rules to follow for any new stock. Check them out here...